|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:acquisition
|
gptkb:Ranbaxy_Laboratories
|
|
gptkbp:ceo
|
gptkb:J._Scott_Mc_Culloch
|
|
gptkbp:clinical_trial
|
ongoing
|
|
gptkbp:conducts_research_on
|
gptkb:Dr._Masato_Saito
|
|
gptkbp:founded
|
gptkb:2005
|
|
gptkbp:founder
|
gptkb:Daiichi_Sankyo_Company,_Limited
|
|
gptkbp:global_presence
|
over 20 countries
|
|
gptkbp:headquarters
|
gptkb:Tokyo,_Japan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Daiichi Sankyo, Inc.
|
|
gptkbp:industry
|
gptkb:pharmaceuticals
|
|
gptkbp:market_cap
|
$40 billion (2021)
|
|
gptkbp:number_of_employees
|
approximately 15,000
|
|
gptkbp:partnership
|
gptkb:GSK
gptkb:Johnson_&_Johnson
gptkb:Takeda_Pharmaceutical_Company
gptkb:Astra_Zeneca
gptkb:Sanofi
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Eisai_Co.,_Ltd.
gptkb:Pfizer
gptkb:Regeneron_Pharmaceuticals
gptkb:Merck_&_Co.
gptkb:Roche
gptkb:Amgen
gptkb:Otsuka_Pharmaceutical
gptkb:Sandoz
gptkb:Chugai_Pharmaceutical
gptkb:Astellas_Pharma
gptkb:Vertex_Pharmaceuticals
gptkb:Abb_Vie
gptkb:Mitsubishi_Tanabe_Pharma
gptkb:Novartis
gptkb:Kyowa_Kirin
Daiichi Sankyo Group.
|
|
gptkbp:philanthropy
|
gptkb:Daiichi_Sankyo_Foundation_of_Life_Science
|
|
gptkbp:products
|
antibiotics
vaccines
oncology drugs
|
|
gptkbp:research_focus
|
rare diseases
central nervous system disorders
cardiovascular diseases
infectious diseases
metabolic diseases
|
|
gptkbp:revenue
|
$10 billion (2020)
|
|
gptkbp:stock_symbol
|
4568. T
|
|
gptkbp:subsidiary
|
gptkb:Daiichi_Sankyo,_Inc._USA
gptkb:Daiichi_Sankyo_Europe_Gmb_H
|
|
gptkbp:type
|
gptkb:public_company
|
|
gptkbp:website
|
www.daiichisankyo.com
|
|
gptkbp:bfsParent
|
gptkb:Daiichi_Sankyo
|
|
gptkbp:bfsLayer
|
5
|